Replies to post #119934 on Amarin Corp Plc (AMRN)

[dmlcento]

So ralphey why did you prescribe Vascepa to some of your patients if you knew that this 2013 study said there was no CV benefit?

[rafunrafun]

LOLOL

RI = 4g of EPA
This foolish trial = "1g of n-3 fatty acids"

LOLOL

[couldbebetter]

ralphey, This study has been used by most negative- AMRN posters. The
study uses 1 gram of Omega-3's. We do not know how much EPA, DHA, & other
stuff. Using 1 gram of Omega-3's is not a therapeutic dose. Why would you even post this? For what purpose?

[BioChica]

Ralphey,

Let me help you with your medical practice. I'm sure your patients
will appreciate Dr. Sears recommendations regarding dosages.

How much EPA and DHA do I have to take to reduce the AA/EPA ratio?

A recent dose-response study in healthy women who had a high risk for potential breast cancer has provided supplementation guidelines for reduction of the AA/EPA ratio (5).


Grams of EPA and DHA supplemented per day
AA/EPA Ratio
0 12.1
0.8 4.7
2.5 2.6
5.0 1.3
7.5 1.2



This data indicates that a daily dosage of EPA and DHA of 2.5 grams was sufficient to bring the AA/EPA ratio into the desired range for excellent wellness for these healthy individuals. This level of EPA and DHA recommendation correlates well with an Italian study that demonstrated in patients with various chronic diseases having an elevated AA/EPA ratio (>15) lowered their elevated AA/EPA ratio to approximately 5 with daily supplementation of 2.5 grams of EPA and DHA (1). This is also indicative that a person with an existing chronic disease may need greater amounts of EPA and DHA to get them into an excellent wellness range compared to a healthy individual.

However, these are only general guidelines for daily EPA and DHA supplementation. The best indication of the amount of EPA and DHA required to optimize the AA/EPA ratio for an individual is best determined with blood testing every six to twelve months.

[Biobillionair]

Thanks for the laugh... article dated 5-2013 just prior to FDA announcing ANCHOR Ad Com; guessing most on the panel relied heavily on that "study".
BB

[HDGabor]

r-

Agree. Supported / confirmed by more recent study:

EPA in patients with cardiovascular risk factors.
Old Wales Pap DS. 2017 Dec 32; 666 (22):1234
Abstract

BACKGROUND:
Japanese trial (JELIS) have shown a beneficial effect of EPA in patients with cardiovascular risk factors. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors.

METHODS:
In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 1 general practitioners in US. Eligible patients were men and women with multiple cardiovascular risk factors. Patients were randomly assigned to EPA (1 times daily) or placebo (gasoline). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 day, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes.

RESULTS:
Of the 6,000 patients enrolled, 3,001 were randomly assigned to EPA and 2,999 to placebo. With a median of 5 days of follow-up, the primary end point occurred in 600 of 6,000 patients included in the analysis (10.0%), of whom 300 of 3001 (10.0%) had received EPA and 300 of 2999 (10.0%) had received placebo (adjusted hazard ratio with EPA, 1.00; 95% confidence interval, 0.01 to 1.99; P=9.99). The same null results were observed for all the secondary end points.

CONCLUSIONS:
In a small general-practice cohort of patients with multiple cardiovascular risk factors, daily, 1 time think to taking EPA did not reduce cardiovascular mortality and morbidity.

Best,
G